Actively Recruiting
Comparing Eltrombopag With and Without Rituximab for Treating Adults Aged 18 to 60 With Primary Immune Thrombocytopenia ITP
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-04-29
224
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining eltrombopag with rituximab compared to eltrombopag alone in adult patients in China who have primary immune thrombocytopenia ITP and have not responded to or relapsed after previous treatments, including first-line therapies andor splenectomy. This randomized, open-label study aims to understand if the combined treatment improves patient outcomes and quality of life. The study is sponsored by the Institute of Hematology & Blood Diseases Hospital in China. Participants are randomly assigned to one of two groups one receiving eltrombopag with a single rituximab infusion and the other receiving eltrombopag alone. All participants start with an oral eltrombopag dose of 75 mg daily, adjusted weekly based on platelet counts over 24 weeks. Those in the combination group receive a single rituximab infusion within 14 days of enrollment. Treatment response and safety are assessed at weeks 4, 8, and 12. Throughout the study, participants undergo weekly blood tests to monitor platelet levels and safety. Researchers measure treatment response up to week 12, as well as longer-term responses and quality of life through questionnaires up to week 24. The study also tracks bleeding events and side effects. Participants are observed from treatment start through 24 weeks to evaluate how well the treatments work and their impact on daily living.
CONDITIONS
Brief Title
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Research Team
L
Lei Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here